Stay updated on Comparison of Risankizumab vs Methotrexate in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Comparison of Risankizumab vs Methotrexate in Psoriasis Clinical Trial page.

Latest updates to the Comparison of Risankizumab vs Methotrexate in Psoriasis Clinical Trial page
- CheckyesterdayChange DetectedThe footer's ClinicalTrials.gov revision label changed from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe study record presents a completed Phase 3 trial comparing risankizumab with methotrexate for moderate to severe plaque psoriasis. It includes participant eligibility, study outcomes, Brazilian locations, and AbbVie’s individual participant data sharing plan.SummaryDifference48%

- Check22 days agoChange DetectedThe ClinicalTrials.gov page still displays a 403 Forbidden error. Its footer revision changes from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check29 days agoChange DetectedA site-wide NIH announcement was added, advising visitors about updated terminology during the agency’s transition.SummaryDifference1%

- Check36 days agoChange DetectedThe footer revision marker changes from v3.7.1 to v3.7.2. The page still shows a 403 Forbidden error.SummaryDifference0.2%

- Check43 days agoChange DetectedThe footer now identifies the ClinicalTrials.gov site revision as v3.7.1 instead of v3.7.0.SummaryDifference0.2%

Stay in the know with updates to Comparison of Risankizumab vs Methotrexate in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Comparison of Risankizumab vs Methotrexate in Psoriasis Clinical Trial page.